Lilly’s Foundayo shows cardiovascular safety in diabetes trial
We haven't written up this one. Investing.com has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
More in Health & Medicine
CMS finalizes GLOBE Medicare demo but savings trail projections
The Centers for Medicare and Medicaid Services finalized a demonstration program aimed at lowering the prices of drugs in Medicare, but with significantly lower expected savings than previously…
New Easier-to-Use GLP-1 Pill Safe for the Heart, Study Says
(MedPage Today) -- Orforglipron (Foundayo) was able to claim cardiovascular safety based on the ACHIEVE-4 trial, though heart benefits remain unproven.
Fitbit data reveal a link between teens’ erratic sleep and how they handle emotions
Teens whose sleep length swings from night to night report more anxiety and sadness, a Fitbit-based study of 1,371 adolescents finds.
Daily pill could offer alternative to insulin injections for diabetes patients at cardiovascular risk
New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct.
Mauritius is the first country to show it is reversing the type 2 diabetes epidemic using gold-standard testing
New research presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct.
Real-world findings suggest GLP-1 drugs offer health benefits for young people with diabetes
New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, from Sept. 28–Oct.